Mangala Nadkarni, MD
Neurology · Livingston, NJNPI 1134231863
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,219 of the $2,514 with a category attached, or 88.3%. It is spread thinly across 36 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 139 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$473
- Harmony Biosciences LLC$299
- AbbVie$236
- Avadel CNS Pharmaceuticals, LLC$225
- Sunovion Pharmaceuticals Inc.$214
- SK Life Science, Inc.$139
- plus $927 from 30 others
Across 17 payments — averaging $4159.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$71K
What the payments were for
- Food & beverage$2,21988%
- Education$29512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 23 | $473 |
| Harmony Biosciences LLC | 13 | $299 |
| AbbVie | 15 | $236 |
| Avadel CNS Pharmaceuticals, LLC | 15 | $225 |
| Sunovion Pharmaceuticals Inc. | 15 | $214 |
| SK Life Science, Inc. | 8 | $139 |
| Neuropace, Inc. | 1 | $96 |
| UCB, Inc. | 5 | $82 |
| Itamar Medical Inc | 2 | $76 |
| Novartis | 3 | $50 |
| Immedica Pharma US, Inc. | 3 | $45 |
| Livanova USA, Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $40 |
| Fisher & Paykel Healthcare Inc | 1 | $38 |
| Pfizer | 2 | $38 |
| Otter Pharmaceuticals, LLC | 2 | $35 |
| Aquestive Therapeutics, Inc. | 2 | $32 |
| Tris Pharma Inc | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Amgen | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Nobelpharma America, LLC | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $17 |
| Resmed Corp | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Sanofi | 1 | $14 |
| Aprecia Pharmaceuticals, LLC | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Aucta Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,514 in reported general payments places this provider in the 55th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 66 | $137,992 |
| Keppra XrLevetiracetam | 18 | $37,341 |
| FycompaPerampanel | 22 | $26,928 |
| BriviactBrivaracetam | 12 | $17,029 |
| Lamotrigine ErLamotrigine | 14 | $13,864 |
| Lacosamide | 114 | $7,998 |
| Levetiracetam ErLevetiracetam | 30 | $6,386 |
| QuviviqDaridorexant Hcl | 12 | $5,837 |
| DilantinPhenytoin Sodium Extended | 14 | $4,776 |
| DayvigoLemborexant | 13 | $4,541 |
| Rufinamide | 25 | $4,439 |
| Levetiracetam | 151 | $4,230 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $3,832 |
| Lamotrigine | 254 | $3,824 |
| TegretolCarbamazepine | 12 | $3,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $139 | $137,99266 claims |
| UCB, Inc.Briviact | $82 | $17,02912 claims |
| PfizerDilantin | $38 | $4,77614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 521 neurology providers in New Jersey.
Other neurology in Livingston
- Matthew TremblayLivingston$35K
- Yanchun ZhangLivingston$35K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.